SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals

Faruqi & Faruqi, LLP, a national securities litigation firm, is investigating possible legal claims on behalf of investors who purchased or acquired securities of Telix Pharmaceuticals Limited (NASDAQ: TLX) between February 21, 2025 and August 28, 2025 and suffered financial losses. The firm, led by Securities Litigation Partner James (Josh) Wilson, is reminding shareholders of the **January 9, 2026 deadline** to file a motion to be appointed lead plaintiff in the federal securities class action that has been filed against Telix. The class action complaint alleges that Telix and its executives violated federal securities laws by making false and misleading statements or omissions about the company’s progress in developing prostate cancer therapeutic candidates, the quality of its supply chain and partner relationships, and overall business prospects. When true information became public—such as an SEC subpoena and an adverse FDA Complete Response Letter regarding its TLX250‑CDx product—Telix’s American Depositary Shares reportedly dropped sharply, causing damages to investors. Investors affected are encouraged to contact Faruqi & Faruqi, including whistleblowers, former employees, and others with relevant information, to discuss their rights and legal options before the deadline. #TelixPharmaceuticals #ClassAction #SecuritiesLitigation #InvestorRights #SlimScan #GrowthStocks #CANSLIM